• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Badhri Srinivasan

Quote

anonymous

Guest
A fish rots from the head down...

You are not only an idiot, but also the worst kind of leader a company can expect: arrogant, ignorant and stubborn.
Your crap decisions will have huge consequences not only for the associates who will lose their job, but also for the company. You can make as many forgery audit as you want, we all know how this plan will end: HYDERABADLY.

Dermott Kenny: Coward is not (yet) a Novartis value, I wonder how can you justify for even a tenth of your fat salary.
 








The fact that Vas and Bhadri were celebrating the "success" of GDD two months after the implementation of the inclusion of GenMed and OGD and 9 months in advance of 01Jul drop dead date just shows their mindsets (read: party in november of last year). We were all wondering what in the hell they were talking about considering GDD HAD DONE NOTHING TO DATE. They are so full of shit it's unreal. And they will bring down the once great company.

Just ridiculous that they're allowed to do this..
 








I blame Vas more then Badhri. He is the leader of development, and Badhri was his hire. If Vas wasn't so worried about KPIs, metrics, and "increasing" efficiency he'd be able to see the bigger picture. Sure, there are some people who are sitting and just waiting for retirement here, but the majority of people work really hard to ensure trials are done correctly, timely, and with good quality. Moving things to India may decrease costs for a bit, but what happens when quality takes a hit? Other companies have tried this and failed, but NVS management thinks they're smarter and better then other companies, it could never fail here right? We will see in 2-3 years if this works, but if it doesn't...Vas will just move on, probably get a CEO position at some other biotech/pharma, and leave NVS to deal with the aftermath.
 




































Conflict of interests? all positions from stat programming and DM are moved to India, and what cannot go there will be outsourced...Hum, Badhri comes from Quintiles, Dermott Kenny from Icon.... To whom will they outsource?
 








anonymous said:
A fish rots from the head down...

You are not only an idiot, but also the worst kind of leader a company can expect: arrogant, ignorant and stubborn.
Your crap decisions will have huge consequences not only for the associates who will lose their job, but also for the company. You can make as many forgery audit as you want, we all know how this plan will end: HYDERABADLY.

Dermott Kenny: Coward is not (yet) a Novartis value, I wonder how can you justify for even a tenth of your fat salary.
Click to expand...

Novartis Value? value of what? every day or other corruption scam in one or other country in the world
 












I think this new management is sending a very positive message to the organization: Being an idiot, with no pharma experience is not a limitation anymore, you could even end up head of GDO or CEO !
 








Top Bottom
Back
Quote